Waldencast Enhances Financial Position with Trademark Sale and New Credit Facility

Waldencast ( (WALD) ) has issued an announcement.

On November 14, 2025, Waldencast plc announced the sale of its rights to the ‘Obagi’ trademark in Japan to Rohto Pharmaceutical Co., Ltd. for $82.5 million. This transaction, along with a new $225 million credit agreement with Lumina Capital Management, strengthens Waldencast’s balance sheet and liquidity position, allowing the company to invest in its Obagi Medical and Milk Makeup brands. These strategic moves are part of Waldencast’s ongoing review to maximize shareholder value and improve its capital structure.

The most recent analyst rating on (WALD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Waldencast stock, see the WALD Stock Forecast page.

Spark’s Take on WALD Stock

According to Spark, TipRanks’ AI Analyst, WALD is a Neutral.

Waldencast Acquisition’s overall stock score is primarily impacted by its financial performance and valuation. The company shows strong revenue growth and a solid balance sheet, but struggles with profitability and cash flow generation. Technical analysis indicates a bearish trend with potential oversold conditions. The negative P/E ratio and lack of dividend yield further weigh down the score.

To see Spark’s full report on WALD stock, click here.

More about Waldencast

Waldencast plc is a global multi-brand beauty and wellness platform focused on developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. The company aims to build a best-in-class operating platform in the beauty and wellness industry, with a brand-led business model ensuring customer proximity, business agility, and market responsiveness.

Average Trading Volume: 221,070

Technical Sentiment Signal: Sell

Current Market Cap: $218.4M

Find detailed analytics on WALD stock on TipRanks’ Stock Analysis page.